Additionally, blocking sialylation with pharmacological agents like ambroxol sensitizes the tumor to immune checkpoint blockade (ICB) therapies, such as anti-PD-1 and anti-CTLA4, significantly improving tumor control and extending survival in preclinical models. Here, CTLA4 is linked to neoplasm.